JohnSKauhMDFACP

Oncology • New Brunswick, NJ

Gastrointestinal Cancer, Hematologic Oncology

Chief Medical Officier Tvardi Therapeutics

Join to view full profile

Dr. Kauh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kauh's full profile

Already have an account?

Office
195 Little Albany Street
New Brunswick, NJ 08901
Phone+1 732-235-7066

Fax+1 732-235-8234
Is this information wrong?

Education & Training

Georgetown University HospitalFellowship, Medical Oncology, 2000 - 2003
Baylor College of MedicineResidency, Internal Medicine, 1997 - 2000
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1997

Certifications & Licensure

NJ State Medical License 2015 - 2025
GA State Medical License 2003 - 2017
DC State Medical License 2000 - 2008
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma Start of enrollment: 2004 Sep 01
Terminated
Phase 2
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer Start of enrollment: 2006 Jan 01
Terminated
Phase 1
Study of MLN4924 in Adult Patients With Nonhematologic Malignancies Start of enrollment: 2008 Apr 01
Completed
Phase 1
A Phase I Trial of Bortezomib and Sunitinib Start of enrollment: 2008 Feb 01
Completed
Phase 1
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors Start of enrollment: 2010 Sep 01
Completed
Phase 1
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Start of enrollment: 2017 Oct 25
Recruiting
Phase 1
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Start of enrollment: 2019 Sep 26
Active, not recruiting
Phase 1
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Start of enrollment: 2019 Aug 26
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

23 citations
LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 do...
Afshin Dowlati, R. Donald Harvey, Richard D. Carvajal, Omid Hamid, Samuel J. Klempner, John S. Kauh, Daniel A. Peterson, Danni Yu, Sonya C. Chapman, Anna M. Szpurka, M...> ;Investigational New Drugs. 2021 Feb 23
27 citations
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Karen A. Autio, Christopher A. Klebanoff, David Schaer, John S. Kauh, Susan F. Slovin, Matthew Adamow, Victoria S. Blinder, Manisha Brahmachary, Michelle Carlsen, Eliz...> ;Clinical Cancer Research. 2020 Aug 26
6 citations
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ...
Neal J. Meropol, Yang Feng, Jean L. Grem, Mary F. Mulcahy, Paul J. Catalano, John S. Kauh, Michael J. Hall, Joel N. Saltzman, Thomas J. George, Jeffrey Zangmeister, El...> ;Cancer. 2018 Feb 15
56 citations
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
Anthony W. Tolcher, Jordan Berlin, Jan Cosaert, John S. Kauh, Emily Chan, Sarina Anne Piha-Paul, Alex Amaya, Shande Tang, Kyla Driscoll, Richard Kimbung, S. R. Prasad ...> ;Cancer Chemotherapy and Pharmacology. 2017 Mar 9
18 citations
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer
Linda T. Vahdat, Rachel M. Layman, Denise A. Yardley, William J. Gradishar, Mohamad Adham Salkeni, Anil A. Joy, Agustin A. Garcia, Patrick J. Ward, James Khatcheressia...> ;The Oncologist. 2017 Mar 1
17 citations
Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors
Patricia LoRusso, Mrinal M. Gounder, Shadia I. Jalal, Valerie Andre, Siva Rama Prasad Kambhampati, Nick Loizos, Jennifer Hall, Timothy R. Holzer, Aejaz Nasir, Jan Cosa...> ;Investigational New Drugs. 2017 Feb 4
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after ...
Moore M, Gill S, Asmis T, Berry S, Burkes R, Zbuk K, Alcindor T, Jeyakumar A, Chan T, Rao S, Spratlin J, Tang PA, Rothenstein J, Chan E, Bendell J, Kudrik F, Kauh J, T...> ;Ann. Oncol.. 2016-12-01
15 citations
An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Danny N. Khalil, Michael A. Postow, Nageatte Ibrahim, Dale L. Ludwig, Jan Cosaert, Siva Rama Prasad Kambhampati, Shande Tang, Dmitri O. Grebennik, John S. Kauh, Heinz-...> ;Clinical Cancer Research. 2016 Nov 1
57 citations
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Thr...
Daniel P. Petrylak, Scott T. Tagawa, Manish Kohli, Andrea Eisen, Christina Canil, Srikala S. Sridhar, Alexander I. Spira, Evan Y. Yu, John M. Burke, David R. Shaffer, ...> ;Journal of Clinical Oncology. 2016 Sep 27
55 citations
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and...
Muhammad Wasif Saif, James A. Knost, E. Gabriela Chiorean, Siva Rama Prasad Kambhampati, Danni Yu, Bronislaw Pytowski, Amy Qin, John S. Kauh, Bert H. O'Neil> ;Cancer Chemotherapy and Pharmacology. 2016 Aug 26
129 citations
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen, Jeffrey W. Clark, John S. Kauh, Glen J. Weiss, James M. Cleary, Devalingam Mahalingam, Michael D. Pickard, Hél...> ;Clinical Cancer Research. 2016 Feb 15
20 citations
Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer.
Natalyn Hawk, Tua-Elisabeth Long, Muhammad H Imam, Blessy M Mathew, Sungjin Kim, Zhengjia Chen, Michael Goodman, Patrick S. Sullivan, Edith Brutcher, John S. Kauh, Shi...> ;American Journal of Clinical Oncology. 2015 Dec 1
35 citations
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
David Smith, Thea Kalebic, Jeffrey R. Infante, Lillian L. Siu, Daniel C. Sullivan, Gordana Vlahovic, John S. Kauh, Feng Gao, Allison Berger, Stephen Tirrell, Neeraj Gu...> ;Investigational New Drugs. 2015 Mar 18
1 citations
Microvessel Density Analysis in Patients with Viral Hepatitis-Related Hepatocellular Carcinoma
Amr Mohamed, Avantika Chenna, Mohamed M. Abdelfatah, Jain Sanjay, M. K. Mohammad, Ibrahim Saber, John S. Kauh, Balsam Elhammali, Ahmed Kaseb> ;Journal of Gastrointestinal Cancer. 2015 Feb 3
53 citations
Survival, Efficacy, and Safety of Small Versus Large Doxorubicin Drug-Eluting Beads TACE Chemoembolization in Patients With Unresectable HCC
Hasmukh J. Prajapati, Minzhi Xing, James R. Spivey, S.I. Hanish, Bassel F. El-Rayes, John S. Kauh, Zhengjia Chen, Hyun Soo Kim> ;AJR. American Journal of Roentgenology. 2014 Nov 21
20 citations
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group
Kristen K. Ciombor, Yang Feng, Al B. Benson, Yingjun Su, Linda W. Horton, Sarah P. Short, John S. Kauh, Charles A. Staley, Mary F. Mulcahy, Mark Powell, Katayoun I. Am...> ;Investigational New Drugs. 2014 Jun 4
10 citations
Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma.
Walid L. Shaib, Rahul Sharma, Edith Brutcher, Sungjin Kim, Shishir K. Maithel, Zhengjia Chen, David A. Kooby, John S. Kauh, Jerome C. Landry, Bassel F. El-Rayes> ;Journal of Surgical Oncology. 2014 May 1
12 citations
The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma
William A. Hall, Lauren E. Colbert, Dana Nickleach, Jeffrey M. Switchenko, Yuan Liu, Theresa W. Gillespie, Joseph Lipscomb, Claire W. Hardy, David A. Kooby, Roshan S. ...> ;Journal of Gastrointestinal Oncology. 2014 Apr 18
37 citations
Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base
Lauren E. Colbert, William A. Hall, Dana Nickleach, Jeffrey M. Switchenko, David A. Kooby, Yuan Liu, Theresa W. Gillespie, Joseph Lipscomb, John S. Kauh, Jerome C. Landry> ;Cancer. 2014 Feb 15
153 citations
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Hemchandra Mahaseth, Edith Brutcher, John S. Kauh, Natalyn Hawk, Sungjin Kim, Zhengjia Chen, David A. Kooby, Shishir K. Maithel, Jerome C. Landry, Bassel F. El-Rayes> ;Pancreas. 2013 Nov 1
10 citations
The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma.
William A. Hall, Lauren E. Colbert, Yuan Liu, Theresa W. Gillespie, Joseph Lipscomb, Claire W. Hardy, David A. Kooby, Roshan S. Prabhu, John S. Kauh, Jerome C. Landry> ;Cancer. 2013 Jun 15
102 citations
Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study
Shoaib Rafi, S.M. Piduru, Bassel F. El-Rayes, John S. Kauh, David A. Kooby, Juan M. Sarmiento, Hyun Soo Kim> ;Cardiovascular and Interventional Radiology. 2013 Apr 1
22 citations
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies
R. D. Harvey, Taofeek K. Owonikoko, Colleen Lewis, A. Akintayo, Zhengjia Chen, Mourad Tighiouart, Suresh S. Ramalingam, P Nadella, Andre Rogatko, Dong M. Shin, Bassel ...> ;British Journal of Cancer. 2013 Mar 5
63 citations
Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma
Hasmukh J. Prajapati, Renumathy Dhanasekaran, Bassel F. El-Rayes, John S. Kauh, Shishir K. Maithel, Zhengjia Chen, Hyun Soo Kim> ;Journal of Vascular and Interventional Radiology. 2013 Mar 1
100 citations
mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated b...
Hasmukh J. Prajapati, James R. Spivey, S.I. Hanish, Bassel F. El-Rayes, John S. Kauh, Zhengjia Chen, Hyun Soo Kim> ;Annals of Oncology. 2013 Apr 1
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Association for Cancer Research - AACR
Member
American College of Physicians - ACP
Fellow